CFO transition at NeuroOne (NASDAQ: NMTC) as Volker steps up

Rhea-AI Filing Summary

NeuroOne Medical Technologies announced a planned chief financial officer transition. Ronald McClurg intends to retire as CFO effective June 30, 2026, and will remain with the company as a Senior Advisor until December 31, 2026 to support an orderly handover.

Chief Operating Officer Christopher Volker will become CFO on July 1, 2026. The company highlights his prior senior roles at Abbott, Cardiovascular Systems and St. Jude Medical, as well as investment banking experience in healthcare and technology.

Volker’s base salary will increase to $350,000 with other key employment terms unchanged. NeuroOne and McClurg entered into a Transition and Release Agreement under which he continues current salary and benefits through his Retirement Date in exchange for a general release of claims and customary restrictive covenants.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Incoming CFO base salary: $350,000 per year CFO retirement effective date: June 30, 2026 Senior Advisor period end: December 31, 2026 +1 more

4 metrics

Incoming CFO base salary $350,000 per year Base salary for Christopher Volker as CFO

CFO retirement effective date June 30, 2026 Date Ronald McClurg retires as CFO

Senior Advisor period end December 31, 2026 Retirement Date for McClurg’s employment

New CFO start date July 1, 2026 Effective date of Christopher Volker as CFO

Key Terms

Transition and Release Agreement, general release of claims, restrictive covenants, Emerging Growth Company

4 terms

Transition and Release Agreement financial

"In connection with Mr. McClurg’s anticipated retirement, he and the Company entered into a Transition and Release Agreement"

general release of claims financial

"In exchange for the payments made under the Transition Agreement, Mr. McClurg provides a general release of claims"

restrictive covenants financial

"and agrees to customary restrictive covenants"

Restrictive covenants are contract terms that limit what a company, its executives, or shareholders can do—like rules that prohibit selling stock, starting a rival business, or taking on certain debts. Think of them as house rules that protect one party’s interests by keeping risky or competitive actions off the table. For investors they matter because these limits affect a company’s flexibility, governance, potential future value and the ease of exiting an investment.

Emerging Growth Company regulatory

"Emerging Growth Company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Understanding 8-K Material Events →

false 0001500198 0001500198 2026-04-24 2026-04-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): April 24, 2026

NeuroOne Medical Technologies Corporation

(Exact name of registrant as specified in its charter)

Delaware		001-40439		27-0863354
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

7599 Anagram Dr., Eden Prairie, MN 55344

(Address of principal executive offices and zip code)

952-426-1383

(Registrant’s telephone number including area code)

(Registrant’s former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		NMTC		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 24, 2026, Ronald McClurg notified NeuroOne Medical Technologies Corporation (the “Company”) of his intention to retire as the Company’s Chief Financial Officer. The effective date of Mr. McClurg’s retirement as Chief Financial Officer will be June 30, 2026. Following his retirement as an officer, Mr. McClurg will remain employed by the Company as a Senior Advisor, to ensure a smooth transition of duties, until December 31, 2026 (the “Retirement Date”).

In connection with Mr. McClurg’s retirement, the Board announced that Christopher Volker, the Company’s Chief Operating Officer, will succeed Mr. McClurg as the Company’s Chief Financial Officer effective as of July 1, 2026. Mr. Volker has extensive experience in the medtech industry, including senior leadership roles at Abbott, Cardiovascular Systems, Inc. (“CSI”), and St. Jude Medical. At CSI, he served as Vice President & General Manager of International and had direct responsibility for international P&L and commercial expansion, including sales, training & education, marketing, business development and program management. Prior to CSI, Mr. Volker held executive leadership roles at St. Jude Medical, including senior roles in corporate finance where he reported directly to St. Jude Medical’s Chief Financial Officer.

He began his career in healthcare and technology investment banking, where he developed expertise in financial analysis, mergers and acquisitions, strategic planning, growth equity investments and financings. Mr. Volker earned a Bachelor of Arts degree from St. John’s University and a Master of Business Administration in Finance from the Wharton School at the University of Pennsylvania. Mr. Volker holds the Chartered Financial Analyst® designation.

Mr. Volker’s base salary will be increased to $350,000 in connection with his appointment as Chief Financial Officer, but the other compensatory and material terms of Mr. Volker’s employment with the Company will remain unchanged.

 In connection with Mr. McClurg’s anticipated retirement, he and the Company entered into a Transition and Release Agreement, dated as of April 28, 2026 (the “Transition Agreement”), pursuant to which Mr. McClurg will continue to receive his current salary and employment benefits until the Retirement Date, at which time his employment with the Company will cease. In exchange for the payments made under the Transition Agreement, Mr. McClurg provides a general release of claims, and agrees to customary restrictive covenants.

The foregoing description of the Transition Agreement is qualified in its entirety by reference to the text of the Transition Agreement. The form of the Transition Agreement is attached as Exhibit 10.1 hereto and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
10.1		Transition and Release Agreement, by and between the Company and Ronald McClurg, dated April 28, 2026
104		Cover Page Interactive Data File (embedded with Inline XBRL document).

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NEUROONE MEDICAL TECHNOLOGIES CORPORATION
Dated: April 30, 2026
	By:	/s/ David Rosa
		David Rosa
		Chief Executive Officer

2

FAQ

What executive leadership change did NeuroOne (NMTC) disclose?

NeuroOne announced that CFO Ronald McClurg will retire as chief financial officer on June 30, 2026. Chief Operating Officer Christopher Volker will assume the CFO role on July 1, 2026, ensuring continuity in the company’s senior financial leadership team.

When will NeuroOne CFO Ronald McClurg fully leave the company?

Ronald McClurg will step down as CFO on June 30, 2026 but remain employed as a Senior Advisor until December 31, 2026. This extended advisory period is intended to support a smooth transition of responsibilities to his successor, Christopher Volker.

Who is NeuroOne’s incoming CFO and what is his background?

NeuroOne’s incoming CFO is Chief Operating Officer Christopher Volker. He brings extensive medtech experience from senior roles at Abbott, Cardiovascular Systems and St. Jude Medical, plus prior healthcare and technology investment banking work and an MBA in Finance from the Wharton School.

How will Christopher Volker’s compensation change as NeuroOne CFO?

In connection with his appointment as CFO, Christopher Volker’s base salary will increase to $350,000. The filing states that other material terms of his employment with NeuroOne will remain unchanged, indicating a targeted adjustment focused on his expanded responsibilities.

What are the key terms of Ronald McClurg’s Transition and Release Agreement?

Under the Transition and Release Agreement, Ronald McClurg will continue to receive his current salary and benefits until December 31, 2026. In exchange, he provides a general release of claims and agrees to customary restrictive covenants, formalizing the terms of his retirement transition.

Filing Exhibits & Attachments

4 documents

Agreements & Contracts

• EX-10.1 TRANSITION AND RELEASE AGREEMENT, BY AND BETWEEN THE COMPANY AND RONALD MCCLURG, 64.0 KB

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB